logo
  

Britvic Q1 Revenue Down, Backs EBIT View; Confident Of Profitable Growth In FY15

Soft drinks maker Britvic Plc (BVIC.L) reported Tuesday that its first-quarter group revenue edged down 0.4 percent at constant exchange rate basis from last year to 304.3 million pounds, driven by a marginal volume decline of 0.3 percent.

The company said its trading in the quarter, as expected, reflected the challenging trading conditions in core markets. However, the company remains confident of delivering EBIT in the previously stated guidance range of 164 million pounds to 173 million pounds, underpinned by cost saving initiatives.

In the quarter, GB revenue declined 1.4 percent, in a notably more competitive promotional environment, while Ireland revenue increased 2.8 percent and France revenue increased 2.3 percent.

International revenue declined 3.6 percent, mainly due to lower volumes in the travel sector combined with lower orders for US concentrate compound.

Simon Litherland, Chief Executive, said, "Whilst we expect the trading environment to remain challenging, we have strong marketing plans and a significant innovation pipeline in place for 2015. These strong commercial plans, supported by ongoing cost benefits from our major strategic initiatives programme, mean that we remain confident of delivering further profitable growth in 2015 in line with our guidance range."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT